Loading
Bios Life runs a virtual clinic for people who have finished cancer treatment or who carry a high inherited risk: a care team watches their risk over time and uses AI models to decide which scan or test should come next and when.
Bios Life describes itself as an AI-native cancer surveillance company. It combines multi-modality foundation models with direct patient care, delivered virtually by licensed care teams across the United States, to personalise screening for people at high risk and follow-up for cancer survivors. It emerged from stealth in August 2026 with USD 25 million in seed financing led by Redmile, Vsquared Ventures and Kindred Capital, and announced a multi-year alliance with Tempus giving it access to de-identified multimodal oncology datasets to train and validate its models, together with genetic screening through Ambry Genetics, a Tempus company. Its co-founders are chief executive Ryan Richardson and Zach Taylor, both formerly of BioNTech, and chief medical officer Logan Frank, a radiologist. The company said its platform would launch in the US in the second half of 2026.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Seed · Led by Redmile, Vsquared Ventures and Kindred Capital | 2026 | $25M | einpresswire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Telehealth and hospital-at-home in oncology, Survivorship care and late-effects surveillance.
Shares Telehealth and hospital-at-home in oncology, Survivorship care and late-effects surveillance.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/